ILUVIEN marketing authorisation in Austria
Alimera Sciences has announced that the Austrian Agency for Health and Food Safety, (Osterreichische Agentur fur Gesundheit und Ernahrungssicherheit (AGES), has granted marketing authorisation to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. 'We are excited to receive this marketing authorisation and pleased that DME patients in Austria will have this therapy available to them. We look forward to receiving the additional expected approvals from the UK and other concerned member states as we continue on track with our commercialisation plans in the EU,' said Dan Myers, president and chief executive officer, Alimera Sciences.
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Picture This: Photo Contest Winners
ESCRS 2025 Refractive and Cataract Photo Contest winners.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.